Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 15/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003793 | 1.00 | ITGAV (0.50) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL328142 | 0.90 | ITGAV (0.50) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL327985 | 0.89 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL8268188 | 0.89 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL328179 | 0.88 | ITGAV (0.53) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL327992 | 0.88 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL328141 | 0.88 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL328067 | 0.87 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL10202486 | 0.87 | ITGAV (0.50) | ITGAVITGB6ITGB3ITGA5ITGB1 | |
| SCHEMBL5585150 | 0.87 | ITGAV (0.50) | ITGAVITGB6ITGB3ITGA5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | ITGAV 492/4885ITGB6 376/4885ITGB3 273/4885 |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | ITGAV 455/4885ITGB6 335/4885ITGB3 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.